Third Harmonic Bio Stock Profit Margin
| THRD Stock | USD 11.04 0.75 7.29% |
Third Harmonic Bio fundamentals help investors to digest information that contributes to Third Harmonic's financial success or failures. It also enables traders to predict the movement of Third Stock. The fundamental analysis module provides a way to measure Third Harmonic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Third Harmonic stock.
Third |
Third Harmonic Bio Company Profit Margin Analysis
Third Harmonic's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Third Harmonic Bio has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Third Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 170.96 M | ||||
| Shares Outstanding | 45.06 M | ||||
| Shares Owned By Insiders | 9.04 % | ||||
| Shares Owned By Institutions | 92.30 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | 23.13 X | ||||
| Price To Book | 1.57 X | ||||
| EBITDA | (30.79 M) | ||||
| Net Income | (30.82 M) | ||||
| Cash And Equivalents | 112.73 M | ||||
| Cash Per Share | 25.53 X | ||||
| Total Debt | 3.95 M | ||||
| Debt To Equity | 7.81 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 6.59 X | ||||
| Cash Flow From Operations | (20.43 M) | ||||
| Short Ratio | 14.29 X | ||||
| Earnings Per Share | (0.97) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 51 | ||||
| Beta | 2.86 | ||||
| Market Capitalization | 463.65 M | ||||
| Total Asset | 277.71 M | ||||
| Retained Earnings | (114.22 M) | ||||
| Working Capital | 267.03 M | ||||
| Net Asset | 277.71 M |
About Third Harmonic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Third Harmonic Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Third Harmonic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Third Harmonic Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Third Harmonic Piotroski F Score and Third Harmonic Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Third Harmonic. If investors know Third will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Third Harmonic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Third Harmonic Bio is measured differently than its book value, which is the value of Third that is recorded on the company's balance sheet. Investors also form their own opinion of Third Harmonic's value that differs from its market value or its book value, called intrinsic value, which is Third Harmonic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Third Harmonic's market value can be influenced by many factors that don't directly affect Third Harmonic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Third Harmonic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Third Harmonic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Third Harmonic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.